Dreisbach A, Lertora J
Expert Opin Drug Metab Toxicol. 2008; 4(8):1065-74.
PMID: 18680441
PMC: 2745294.
DOI: 10.1517/17425255.4.8.1065.
Sjostrom P, Kron B, Odlind B
Eur J Clin Pharmacol. 1993; 45(2):135-9.
PMID: 8223834
DOI: 10.1007/BF00315494.
Pentikainen P, Neuvonen P, Kekki M, Penttila A
J Pharmacokinet Biopharm. 1980; 8(3):219-28.
PMID: 7420267
DOI: 10.1007/BF01059643.
Keller E, HOPPE-SEYLER G, Mumm R, Schollmeyer P
Eur J Clin Pharmacol. 1981; 20(1):27-33.
PMID: 7308269
DOI: 10.1007/BF00554663.
Elliott H, Ansari A, Campbell B, Lawrence J
Eur J Clin Pharmacol. 1982; 21(4):311-3.
PMID: 7056276
DOI: 10.1007/BF00637619.
Kinetics of furosemide in children with chronic renal failure undergoing regular haemodialysis.
Riva E, Fossali E, Bettinelli A
Eur J Clin Pharmacol. 1982; 21(4):303-6.
PMID: 7056274
DOI: 10.1007/BF00637617.
Plasma protein binding of furosemide in kidney transplant patients.
Smith D, Benet L
J Pharmacokinet Biopharm. 1982; 10(6):663-74.
PMID: 6763626
DOI: 10.1007/BF01062547.
Alteration of drug-protein binding in renal disease.
Reidenberg M, Drayer D
Clin Pharmacokinet. 1984; 9 Suppl 1:18-26.
PMID: 6705423
DOI: 10.2165/00003088-198400091-00003.
Diuretics. Clinical pharmacology and therapeutic use (Part I).
Lant A
Drugs. 1985; 29(1):57-87.
PMID: 3882391
DOI: 10.2165/00003495-198529010-00003.
Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome.
Sjostrom P, Odlind B, Beermann B, Karlberg B
Eur J Clin Pharmacol. 1989; 37(2):173-80.
PMID: 2792172
DOI: 10.1007/BF00558227.
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).
Zini R, Riant P, Barre J, Tillement J
Clin Pharmacokinet. 1990; 19(3):218-29.
PMID: 2203581
DOI: 10.2165/00003088-199019030-00005.
Plasma protein binding of phenylbutazone during recovery from acute renal failure.
Mussche M, Belpaire F, Bogaert M
Eur J Clin Pharmacol. 1975; 9(1):69-71.
PMID: 1233255
DOI: 10.1007/BF00613431.
Diuretics: mechanism of action and clinical application.
Davies D, WILSON G
Drugs. 1975; 9(3):178-226.
PMID: 1092541
DOI: 10.2165/00003495-197509030-00003.
Binding of four sulphonamides to human albumin.
Zini R, dAthis P, Hoareau A, Tillement J
Eur J Clin Pharmacol. 1976; 10(2):139-45.
PMID: 964290
DOI: 10.1007/BF00609473.
Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.
Andreasen F, Mikkelsen E
Eur J Clin Pharmacol. 1977; 12(1):15-22.
PMID: 902673
DOI: 10.1007/BF00561400.
Determinants of response to frusemide in normal subjects.
Branch R, Roberts C, Homeida M, Levine D
Br J Clin Pharmacol. 1977; 4(2):121-7.
PMID: 861127
PMC: 1429020.
DOI: 10.1111/j.1365-2125.1977.tb00682.x.
Pharmacokinetics of furosemide in gestosis of pregnancy.
Riva E, Farina P, Tognoni G, Bottino S, Orrico C, Pardi G
Eur J Clin Pharmacol. 1978; 14(5):361-6.
PMID: 729629
DOI: 10.1007/BF00611907.
Pharmacokinetics of furosemide in anephric patients and in normal subjects.
Andreasen F, Hansen H, Mikkelsen E
Eur J Clin Pharmacol. 1978; 13(1):41-8.
PMID: 639832
DOI: 10.1007/BF00606681.
Pharmacokinetics/pharmacodynamics of furosemide in man: a review.
Benet L
J Pharmacokinet Biopharm. 1979; 7(1):1-27.
PMID: 458552
DOI: 10.1007/BF01059438.
Clinical pharmacokinetics of frusemide.
Cutler R, Blair A
Clin Pharmacokinet. 1979; 4(4):279-96.
PMID: 385209
DOI: 10.2165/00003088-197904040-00002.
